Skip to main content

Table 1 Clinical characteristics of the patients in this study and of those in the report by Liu and colleagues [7]

From: Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study

Variable This study Data from [7] Pvalue
Age in years, mean ± SD 54.2 ± 13.1 57 ± 13.5 0.06
Age in years at diagnosis, mean ± SD 46.2 ± 13.5 47 ± 15 0.3
Women, percentage 84.8 75 0.06
Disease duration in years, mean ± SD 7.8 ± 6.6 8 ± 8 0.4
Current smokers, percentagea 9.1 15 0.3
Ever smokers, percentagea 25.0   
Rheumatoid factor-positive, percentage 68.9 83.8 0.01
Anti-CCP-positive, percentagea 86.3 61.9 0.0001
Shared epitope-positive, percentagea 58.3   
Antinuclear antibody-positive, percentagea 29.8   
HAQ at baseline, mean ± SD 1.4 ± 0.7 1.1 ± 0.6 0.0005
DAS28 at baseline, mean ± SD 5.6 ± 1.2 5.2 ± 0.8 0.002
DAS28 ≥ 5.1, percentage 70.2   
3.2 ≤ DAS28 > 5.1, percentage 26.5   
DAS28 at 12 to 16 weeks, mean ± SD 3.6 ± 1.4 3.7 ± 1.3 0.2
DAS28 at 6 months, mean ± SD 3.5 ± 1.4   
Good responders at 12 to 16 weeks, percentage 40.4 34.8 0.6
Non-responders at 12 to 16 weeks, percentage 22.5 25.8 0.6
Good responders at 6 months, percentage 43.7   
Non-responders at 6 months, percentage 21.8   
Anti-tumor necrosis factor drug    
   Infliximab, number 101 32 0.01
   Etanercept, number 35 39 0.02
   Adalimumab, number 15 18 0.05
  1. aData were available for 102 patients for anti-cyclic citrullinated peptide (CCP) antibodies, antinuclear antibody, and shared epitope and for 88 patients for smoking habits. DAS28, disease activity score using 28 joint counts; HAQ, health assessment questionnaire; SD, standard deviation.